FACTORS PREDICTIVE FOR TUMOR CONTROL AMONG HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIB

被引：0
|
作者：
Tortora, R. [1 ]
Lanza, A. Galeota [1 ]
Lampasi, F. [1 ]
De Luca, M. [1 ]
Tartaglione, M. T. [1 ]
Pacilio, R. [1 ]
Di Costanzo, G. G. [1 ]
机构：
[1] Cardarelli Hosp, Liver Unit, Naples, Italy
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60662-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
660
引用
收藏
页码：S266 / S266
页数：1
相关论文
共 50 条
  • [21] Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma
    Nagahama, H
    Okada, S
    Okusaka, T
    Ishii, H
    Ikeda, M
    Nakasuka, H
    Yoshimori, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (05) : 321 - 324
  • [22] Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
    Brunetti, Oronzo
    Gnoni, Antonio
    Licchetta, Antonella
    Longo, Vito
    Calabrese, Angela
    Argentiero, Antonella
    Delcuratolo, Sabina
    Solimando, Antonio Giovanni
    Casadei-Gardini, Andrea
    Silvestris, Nicola
    MEDICINA-LITHUANIA, 2019, 55 (10):
  • [23] PREDICTIVE FACTORS OF RESPONSE TO SORAFENIB IN HEPATOCELLULAR CARCINOMA: A RETROSPECTIVE PILOT STUDY
    Castain, C.
    Blanc, J. -F.
    Bioulac-Sage, P.
    Diallo, A.
    Chevet, E.
    Possenti, L.
    Trillaud, H.
    Le-Bail, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S390 - S390
  • [24] SKIN TOXICITY AS A PREDICTIVE FACTOR FOR TUMOR CONTROL IN ADVANCED HCC PATIENTS TREATED WITH SORAFENIB
    Vincenzi, B.
    Montella, L.
    Santini, D.
    Venditti, O.
    Addeo, R.
    Frezza, A.
    Del Prete, S.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 52 - 52
  • [25] SKIN TOXICITY AS A PREDICTIVE FACTOR FOR TUMOR CONTROL IN ADVANCED HCC PATIENTS TREATED WITH SORAFENIB
    Vincenzi, B.
    Santini, D.
    Frezza, A.
    Montella, L.
    Addeo, R.
    Del Prete, S.
    Tonini, G.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S302 - S302
  • [26] EARLY SKIN TOXICITY AS A PREDICTIVE FACTOR FOR TUMOR CONTROL IN HCC PATIENTS TREATED WITH SORAFENIB
    Vincenzi, Bruno
    Montella, Liliana
    Giuliani, Francesco
    Santini, Daniele
    Venditti, Olga
    Addeo, Raffaele
    Frezza, Anna Maria
    Colucci, Giuseppe
    Del Prete, Salvatore
    Tonini, Giuseppe
    ANNALS OF ONCOLOGY, 2009, 20
  • [27] Tumor c-Met expression and prognosis of advanced hepatocellular carcinoma patients treated with sorafenib
    Shao, Yu Yun
    Hsiao, Chi-Huang
    Lee, Ray
    Puig, Oscar
    Chan, Soa-Yu
    Li, Yong-Shi
    Hsu, Chih-Hung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [28] Biomarker analysis using circulating tumor DNA in patients treated with sorafenib for advanced hepatocellular carcinoma
    Park, S. R.
    Oh, C. R.
    Kong, S-Y.
    Kim, M. K.
    Yoon, K-A.
    Cho, E.
    Jang, J-H.
    Lee, J.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Alpha-fetoprotein predicts survival and tumor progression in patients with hepatocellular carcinoma treated with sorafenib
    Pinter, Matthias
    Sieghart, Wolfgang
    Graziadei, Ivo
    Vogel, Andreas
    Maieron, Andreas
    Koenigsberg, Robert
    Kornek, Gabriela
    Peck-Radosavljevic, Markus
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (15-16) : A24 - A24
  • [30] TUMOR NECROSIS AS A CORRELATE FOR RESPONSE IN SUBGROUP OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB
    Abou-Alfa, G. K.
    Zhao, B.
    Capanu, M.
    Guo, P.
    Liu, F.
    Jacobs, G.
    Gansukh, B.
    Moscovici, M.
    Lentini, G.
    Schwartz, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 178 - 178
12345